North American Journal of Medical Sciences

: 2012  |  Volume : 4  |  Issue : 11  |  Page : 537--547

Newer antibacterials in therapy and clinical trial

Simi S Paknikar1, Sarala Narayana2 
1 Consulting Medical Writer and Editor, India
2 Department of Pharmacology, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka, India

Correspondence Address:
Simi S Paknikar
F-502, Nandi Woods, SOS Village Post, Yelenahalli, Begur Hobli, Off Bannerghatta Road, Bangalore- 560 076, Karnataka

In order to deal with the rising problem of antibiotic resistance, newer antibacterials are being discovered and added to existing pool. Since the year 2000, however, only four new classes of antibacterials have been discovered. These include the oxazolidinones, glycolipopeptides, glycolipodepepsipeptide and pleuromutilins. Newer drugs were added to existing classes of antibiotics, such as streptogramins, quinolones, beta-lactam antibiotics, and macrolide-, tetracycline- and trimethoprim-related drugs. Most of the antibacterials are directed against resistant S. aureus infections, with very few against resistant gram-negative infections. The following article reviews the antibacterials approved by the FDA after the year 2000 as well as some of those in clinical trials. Data was obtained through a literature search via Pubmed and google as well as a detailed search of our library database.

How to cite this article:
Paknikar SS, Narayana S. Newer antibacterials in therapy and clinical trial.North Am J Med Sci 2012;4:537-547

How to cite this URL:
Paknikar SS, Narayana S. Newer antibacterials in therapy and clinical trial. North Am J Med Sci [serial online] 2012 [cited 2020 Aug 12 ];4:537-547
Available from:;year=2012;volume=4;issue=11;spage=537;epage=547;aulast=Paknikar;type=0